PHAT Phathom Pharmaceuticals Inc

$PHAT this indication looking likely combined with FCF positive next year should inspire a more assertive bid next year. This Voquezna P-Cab ecosystem being built by PHAT will be worth $4-$5 billion given TAM the next 7-8 yrs.

$PHAT this could be the exact data/presentation we’re looking for. Highlighting how ridiculous PPIs are and how much the drug costs over time compared to the far superior compound of Voquezna and the tangible healing effects. NET/NET - $PHAT Treatment SAVES patients and insurers. GIs would be wise to phase off PPIs and use Voquezna as it works better, heals damage, and has a BETTER safety profile. Cost-Effectiveness of Vonoprazan Versus Proton Pump Inhibitors in Adults With Erosive Esophagitis in the United States: A Markov Model of Lifetime Outcomes Poster: P5160 Time: 10:30 AM – 4:00 PM CDT Presenter: Nicholas J. Shaheen, MD, MPH, Chief of the Division of Gastroenterology and Hepatology and Bozymski-Heizer Distinguished Professor of Medicine at the UNC School of Medicine

$PHAT are people waking up to what a stupid valuation we’re at now? Company will do $1 in earnings next year. Just buy and hold!

$PHAT Phathom Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide Business Update on Thursday, October 29, 2026 BAF!!!! Hope everyone is positioned

$PHAT not often gonna find 300m+ revenue per year 75% growth YoY trading below 600m MC. Some will say concerns around debt and potential compotetion in 2027 will slow growth... not to zero. Debt is high but managable with out refinacing given even slower growtg and inflation helps this company. I dont know how this trades below 1B and isnt a 1.5B BO target on the low side. With everyone looking for a place to put money that will beat inflation and bond rate returns, like being able to buy at this price.

$PHAT So many sad sacks in here. I bought 500 at 6.83 and that’s all it took to break the downtrend. They would not fill 500 more at 6.81. It is complete manipulation with just a handful of shares people

$PHAT big boys that been here a while liked the dip. Accumulated as much as market makers allowed.

$PHAT Reached 20k shares at an $8.64 average. This still feels like no mans land and it may go lower, but if there is one thing I’ve learned is that I’ll never time anything perfectly.

$PHAT this is going to get bought by a company that can negotiate with managed care. Current price was similar to when their patent future was uncertain.

$PHAT I have bought so much today, thanks to the moron market makers. What a bunch of dopes

$PHAT Phathom’s Presentations at ACG 2026: Sunday, October 11, 2026 Vonoprazan Efficacy Across BMI Subgroups in Non-Erosive Reflux Disease Poster: P0624 Time: 3:30 PM – 7:00 PM CDT Presenter: Catiele Antunes, MD, Assistant Professor of Medicine and Director of the Refractory GERD Clinic at Yale School of Medicine

$PHAT machines flipping Pennies, SP doesn’t make sense. If they can pull off a manged care win with a big PBM and show a profit this is off to the races!!!

$PHAT generated a lot of cash today as I prepare to reposition from commercial stage cash drains to on the cusp of profitable 💎 like PHAT. Money going in heavy this week which will be my final blow down here.

$PHAT Once again, a small buy scares the algos into immediately bumping the price, then slowly walking it back down. 49 share purchase at 6.685 made them immediately reprice to 6.74. They are counting on you capitulating like a bunch of long tail cats in a room of rocking chairs

$PHAT still accumulating. I’ve been able to bring my average down to $8.7 again. Fun fact: $6’s was the price when I first entered this stock years ago and weren’t generating nearly the same amount of money. So yes, I will buy more.

$PHAT All this Doom and gloom talk convinced me to pick up another 1400. Looking forward to seeing the updated short figures and the new 13fs next month.

$PHAT Tuesday, October 13, 2026 Cost-Effectiveness of Vonoprazan Versus Proton Pump Inhibitors in Adults With Erosive Esophagitis in the United States: A Markov Model of Lifetime Outcomes Poster: P5160 Time: 10:30 AM – 4:00 PM CDT Presenter: Nicholas J. Shaheen, MD, MPH, Chief of the Division of Gastroenterology and Hepatology and Bozymski-Heizer Distinguished Professor of Medicine at the UNC School of Medicine Attendees can also visit Phathom’s Medical Affairs and Commercial teams on the exhibit floor at Booth 323.

$PHAT good volume for a recover day. Sure wouldn’t mind grabbing a stack and seeing $12/share. No true justification for current SP. Debt is just something bears talk about when you get near the bottom.

$PHAT $GERN $NUVB Several companies with the same price pattern heading into earnings. Bottom fishing only. Regretting some of those choices earlier this month. In at $7.08, $1.26, $5.78. Very tight spot loss.

$PHAT FYI Voquezna TRx for week ending 9/11/26 were 18,497, down 2% wk/wk, down 5% mo/mo. Sure, some holiday effect in here which may be exaggerated given how late Labor Day was, but really need to see Rx rebound hard to set themselves up for hitting consensus Q3 (and FY26) revenue. TRx data for week ending 9/18/26 is out there somewhere and price action is telling me that isn’t happening